Vobramitamab Duocarmazine is a monoclonal antibody conjugated commercialized by MacroGenics, with a leading Phase II program in Castration-Resistant Prostate Cancer (CRPC). According to Globaldata, it is involved in 5 clinical trials, of which 3 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vobramitamab Duocarmazine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vobramitamab Duocarmazine is expected to reach an annual total of $59 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vobramitamab Duocarmazine Overview
MacroGenics is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, HIV, breast and gastroesophageal cancers, type 1 diabetes, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.
The company reported revenues of (US Dollars) US$151.9 million for the fiscal year ended December 2022 (FY2022), an increase of 96.2% over FY2021. The operating loss of the company was US$121.4 million in FY2022, compared to an operating loss of US$202.8 million in FY2021. The net loss of the company was US$119.8 million in FY2022, compared to a net loss of US$202.1 million in FY2021. The company reported revenues of US$10.4 million for the third quarter ended September 2023, a decrease of 20.9% over the previous quarter.
For a complete picture of Vobramitamab Duocarmazine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.